🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Efficacy of Hemostatic Agents

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) NCT07227311Phase 259 sites📍 Los Alamitos📍 Torrance📍 Whittier GlaxoSmithKline · Tests: Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma NCT04973605Phase 1, Phase 274 sites📍 Birmingham📍 Duarte📍 Irvine BeOne Medicines · Tests: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies NCT07101705EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: OriV508 Injection Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). NCT07638683Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Teclistamab Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia NCT05640102n/a8 sites📍 Huntsville📍 Mobile📍 Duarte BeiGene · Tests: Zanubrutinib Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) NCT06759181Phase 1, Phase 21 site📍 Xuzhou Xuzhou Medical University · Tests: anti-BCMA/FcRL5 CAR T Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients NCT07210047Phase 1, Phase 21 site📍 Taipei HuniLife Biotechnology, Inc. · Tests: HuL001, Lenalidomide/Dexamethasone Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 360 sites📍 Orange📍 Denver📍 Coral Springs CSL Behring · Tests: IgPro20 Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis NCT06971380Phase 21 site📍 Jerusalem Polina Stepensky · Tests: HBI0101 CART A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596Phase 1, Phase 212 sites📍 Duarte📍 Denver📍 Tampa AstraZeneca · Tests: AZD4045, Daratumumab, Aldesleukin Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma NCT07555938Phase 393 sites📍 Duarte📍 Irvine📍 New Haven Hoffmann-La Roche · Tests: Cevostamab, Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) NCT06196255Phase 1, Phase 21 site📍 Xuzhou Xuzhou Medical University · Tests: anti-FcRL5 CAR-T Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma NCT04879043Phase 1, Phase 224 sites📍 Atlanta📍 Louisville📍 Omaha Heidelberg Pharma AG · Tests: HDP-101 Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma NCT07581704Phase 11 site📍 Iowa City Christopher Strouse · Tests: Sirolimus, Teclistamab, Talquetamb Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies NCT07270263NA1 site📍 Gdansk Medical University of Gdansk · Tests: Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium) A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT) NCT07743671Phase 34 sites📍 Chicago📍 Indianapolis📍 Rochester Vaderis Therapeutics AG · Tests: Engasertib, Placebo A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma NCT07579234Phase 31 site📍 Tianjing Shandong New Time Pharmaceutical Co., LTD · Tests: F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT07095452Phase 2, Phase 349 sites📍 Scottsdale📍 Los Angeles📍 Denver AbbVie · Tests: Etentamig, Lenalidomide, Daratumumab, Dexamethasone, Dexamethasone A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT07284758Phase 221 sites📍 Huntsville📍 Phoenix📍 Scottsdale C4 Therapeutics, Inc. · Tests: Cemsidomide, Dexamethasone ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders NCT04398628n/a76 sites📍 Phoenix📍 Little Rock📍 Los Angeles American Thrombosis and Hemostasis Network Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients NCT07169500Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CAR-T A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma NCT06049290Phase 1, Phase 221 sites📍 Wuhu📍 Beijing📍 Xiamen Nanjing Leads Biolabs Co.,Ltd · Tests: LBL-034 for Injection A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. NCT07429721EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: QI-019A Injection An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers NCT07226934NA1 site📍 St Louis Washington University School of Medicine · Tests: GPT-QPL a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease NCT04776330Phase 1, Phase 21 site📍 Kunming Chongqing Precision Biotech Co., Ltd · Tests: BCMA targeted prime CAR-T cells A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma NCT07760454Phase 1, Phase 22 sites📍 Suzhou📍 Shanghai UCARsgen Biotech Limited · Tests: CT0596 A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma NCT06574568Phase 112 sites📍 Beijing📍 Beijing📍 Foshan Excyte Biopharma Ltd · Tests: YKST02 CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma NCT07249073EARLY Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CAR19-BCMA dual-target CAR-T A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma NCT07582432Phase 35 sites📍 St. Petersburg📍 Fort Wayne📍 Westbrook Grifols Biologicals, LLC · Tests: Gamunex-C, 10% Injectable Solution
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy